Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 10/20 | 0.77 |
| ▸ | TDP1 | Q9NUW8 | 8/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.77 |
| ▸ | TSHR | P16473 | 5/20 | 0.77 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | S100B | P04271 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30932845 | 1.00 | CYP3A4 (0.77) | CYP3A4TDP1ALDH1A1TSHRTP53 | |
| Hydrochloric Acid SCHEMBL6689078 | 1.00 | CYP3A4 (0.77) | CYP3A4TDP1ALDH1A1TSHRTP53 | |
| SCHEMBL99565 | 0.98 | CYP3A4 (0.81) | CYP3A4TDP1ALDH1A1TSHRTP53 | |
| SCHEMBL29742298 | 0.98 | CYP3A4 (0.81) | CYP3A4TDP1ALDH1A1TSHRTP53 | |
| SCHEMBL8953924 | 0.98 | CYP3A4 (0.81) | CYP3A4TDP1ALDH1A1TSHRTP53 | |
| Orthotolidine SCHEMBL9405146 | 0.98 | CYP3A4 (0.81) | CYP3A4TDP1ALDH1A1TSHRTP53 | |
| SCHEMBL8954009 | 0.91 | CYP3A4 (0.94) | CYP3A4TDP1ALDH1A1TSHRTP53 | |
| Orthotolidine SCHEMBL38664709 | 0.91 | CYP3A4 (0.94) | CYP3A4TDP1ALDH1A1TSHRTP53 | |
| Orthotolidine SCHEMBL867121 | 0.91 | CYP3A4 (0.94) | CYP3A4TDP1ALDH1A1TSHRTP53 | |
| Orthotolidine SCHEMBL3466480 | 0.91 | CYP3A4 (0.94) | CYP3A4TDP1ALDH1A1TSHRTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250180952-A1 | PHOTOALIGNING MATERIALS | Rolic Technologies AG (CH) | 2025-06-05 | — | — | US | disclosed |
| EP-4493638-A1 | PHOTOALIGNING MATERIALS | Rolic Technologies AG (CH) | 2025-01-22 | — | — | EP | disclosed |
| CN-118871548-A | Photoalignment materials | 罗利克技术有限公司 | 2024-10-29 | — | — | CN | disclosed |
| WO-2023174773-A1 | PHOTOALIGNING MATERIALS | Rolic Technologies AG (CH) | 2023-09-21 | — | — | WO | disclosed |
| US-11634544-B2 | Photoaligning materials | Rolic Technologies AG (CH) | 2023-04-25 | — | — | US | disclosed |
| US-20210340330-A1 | PHOTOALIGNING MATERIALS | Rolic Technologies AG (CH) | 2021-11-04 | — | — | US | disclosed |
| CN-108912011-B | Photoalignment material | 罗立克科技股份公司 | 2021-09-24 | — | — | CN | disclosed |
| US-20200223984-A1 | PHOTOALIGNING MATERIALS | Rolic Technologies AG (CH) | 2020-07-16 | — | — | US | disclosed |
| US-10696795-B2 | Photoaligning materials | Rolic Technologies AG (CH) | 2020-06-30 | — | — | US | disclosed |
| EP-3374467-B1 | COMPOSITIONS OF PHOTO-ALIGNABLE MATERIALS | ROLIC TECH AG (CH) | 2020-04-15 | — | — | EP | disclosed |
| EP-2308827-A1 | Photocrosslinkable materials | Rolic AG (CH) | 2011-04-13 | — | — | EP | disclosed |
| EP-2305632-A1 | Photocrosslinkable materials | Rolic AG (CH) | 2011-04-06 | — | — | EP | disclosed |
| EP-2305631-A1 | Photocrosslinkable materials | Rolic AG (CH) | 2011-04-06 | — | — | EP | disclosed |
| US-20100266814-A1 | PHOTOALIGNMENT COMPOSITION | ROLIC AG (CH) | 2010-10-21 | — | — | US | disclosed |
| EP-2222815-A1 | PHOTOALIGNMENT COMPOSITION | Rolic Ltd. (CH) | 2010-09-01 | — | — | EP | disclosed |
| US-20100048849-A1 | PHOTOCROSSLINKABLE MATERIALS COMPRISING ALICYCLIC GROUP | ROLIC AG (CH) | 2010-02-25 | — | — | US | disclosed |
| WO-2009080271-A1 | PHOTOALIGNMENT COMPOSITION | ROLIC LTD. (CH) | 2009-07-02 | — | — | WO | disclosed |
| US-20080293888-A1 | Photocrosslinkable Materials | ROLIC AG (CH) | 2008-11-27 | — | — | US | disclosed |
| EP-1208379-A2 | DETECTION OF ISOMERISED EPITOPES IN AUTOIMMUNE DISEASES | Osteometer Biotech AS (DK) | 2002-05-29 | — | — | EP | disclosed |
| WO-2001013110-A2 | DETECTION OF ISOMERISED EPITOPES IN AUTOIMMUNE DISEASES | OSTEOMETER BIOTECH A/S (DK) | 2001-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048849-A1 | PHOTOCROSSLINKABLE MATERIALS COMPRISING ALICYCLIC GROUP | DDC, ALAD, DYNC1LI1 | ACHE 3250/4885CYP3A4 4068/4885TDP1 840/4885 |
| US-20080293888-A1 | Photocrosslinkable Materials | DDC, PARG, ALAD | ACHE 3996/4885CYP3A4 4202/4885TDP1 914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.